ABCL AbCellera Biologics Inc

$ABCL phenomenal run to from 2s to 14-15 2022 areas of resistance from 2022 - more data tomorrow but think short-term its run a very nice amount in a short amount of time - lot of positivity priced in on VMS - expecting some consolidation/digestion in 10-15 area - but thesis still in tact for LT too to higher levels like 20s later if progress/data keeps up. if you are an investor stick with it prob but if your a trader of it be cautious up here short term

$ABCL Tons of resistance at $15, looks like we're going to need some sort of new catalyst to really break that and hold it. Remember, there's been A TON of bagholding through out the years so as we move higher there's going to be quite a lot of resistance as those that have been stuck, unload and move on. I look forward to our march onward back up to our IPO price! Cheers to all here, it's been quite the fun, exciting rebound from years and years of having our throats stepped on!

$ABCL Love that UBS analysis at $18. Lowest updated one I’ve seen is $13, and most are in the $15-$30 - going to be a big year!!

$ABCL Wow, 320k bought at 10:07, another 133k at 11:54 - huge volume and price soaring with no news. Something know something I don't??

$ABCL gave you the bottom almost to penny and the top both days almost on this run from 1.89 to 15

$ABCL 🔥 Get in NOW!! We GOT a MAJOR CATALYST in a few days!!! After an “IMPRESSIVE & a HOME-RUN of Phase II RESULTS WE have.. Now been INVITED to PRESENT at the LARGEST 2026 TMS “THE MENOPAUSE SOCIETY” in the WORLD 🔥 STARTING NEXT TUESDAY!! 🚨Guess What, we are PRESENTING the 12 WEEK DATA 📊 for Phase II @ this CONFERENCE in front of Millions of People & Institutions and this will make itself known to the ENTIRE WORLD. 👂 🌍 If you thought 💭 that the Move for Phase II result was “BIG” your fooling yourself! This is the “BIG” move we been waiting for. When people hear ABOUT the 12 week Data 📊 and see the Results for themselves for 90 days. 😮 🤯 🔥 BOOM!! We going to SKY ROCKET $18-$23🚀! Carl CEO $ABCL in his own words said “Patient’s were CURED” YES “CURED”!! Patients went from experiencing “10 EVENTS a day to ZERO” in less than 4 weeks!! This is a “f******* “BIG”DEAL!! 🔥 They are going to be ADDING $ABCL to their portfolios and BUYING it UP!! The RESULTS are “flawless”!!! 🤯 🚀

$ABCL 100%. I usually don't post more than a sentence or two, but these rich asshats and their puppets have been jerking this thing back and forth for a while now. 😂😭 Let them play their games. I’ve learned, that they can’t manipulate—PATIENCE. I’ve been in ABCL since it was down around $3. I’ve banked some nice profits along the way, added and traded around my position, and I’m still sitting on plenty of shares for what I believe could be the REAL payday. 💰 I do my own DD and usually keep it to myself! Nothing in biotech is guaranteed. But here’s what has me excited: ABCL does NOT need every program to become a blockbuster. Start getting successful drug candidates into the clinic, advancing through trials, and eventually reaching commercialization—and suddenly you’re talking milestones, royalties, and potentially multiple shots on goal. That’s when this story could get VERY interesting. So manipulate it. Short it. Shake the tree. Scare out the weak hands 😆 It's coming!💰🤑🔥

$ABCL I love the JP Morgan upgrade and especially the physician survey they conducted! The central thesis is that ABCL has reached a major value inflection point following the encouraging ABCL635 Phase 2 data for menopausal hot flashes. J.P. Morgan highlighted ABCL635’s potentially differentiated profile—particularly its efficacy, safety and dosing convenience—and cited a September physician survey in which roughly 60% of respondents said they could see at least 25% of their menopausal hot-flash patients using ABCL635, with the average expected penetration around 38%. The firm also emphasized AbCellera’s extensive pharmaceutical partnerships as validation of its antibody-discovery platform while helping offset development costs. When JP and Goldman starts coverage, you know there is money to be made!

$ABCL Get in NOW or catch yourself paying $13’sss this afternoon!! People we got a Major catalyst in a few days 🔥!!! It’s the 12 week data 📈 📊 on the Phase II Results and can you if imagine they talk about a new molecule?!!!

$ABCL 👀 🙌 Today you have the chance to buy at $11.80’s Close to the same price at which Andrew Booth bought 37,200 shares, Michael Hayden bought over $1M worth, and John Montalbano another $110K 🤓 💡When the CFO and several board members buy over $1.5M out of their own pockets after learning about some spectacular clinical data, and the market gives you the chance to fish in the same river... You guys decide for yourselves… ABcellera ❤️ 🔥 🔥 UPGRADES!!! BOOM!! Price targets 🔵 Truist Securities — $30 🔴 JonesTrading — $25 🟡 UBS — $18 🟢 JPMorgan — $17 🟣 BMO Capital — $15 🟠 Goldman Sachs — $13 🩵 Cantor Fitzgerald — $12 🩷 Stifel — $9 👀🚨🔥JonesTrading analyst Debanjana Chatterjee reiterated a Buy rating on AbCellera Biologics and set a price target of $25.00. She’s actually a very accurate Analyst!! So this is a STRONG SIGNAL $25’ssss!

$ABCL stay focused people….remember what Carl recently said! Carl Hansen appeared at the 12th Annual Cantor Fitzgerald Global Healthcare Conference, interviewed by analyst Steven Seedhouse. Some notable points: * Hansen said the ABCL635 results “blew the doors off” even their most bullish expectations. * He emphasized that ABCL635 isn’t the whole AbCellera story. * He said the platform and future drugs may ultimately be the most valuable part of the company. * ABCL has already put a longer-half-life follow-on to ABCL635 into IND-enabling studies. * Interestingly, Hansen suggested AbCellera may stop announcing development candidates before they enter the clinic, saying disclosure can expose the company without creating much value. * He indicated that two other programs could enter the clinic next year, which could give investors additional catalysts beyond ABCL635

$ABCL $BB these are my two favourites. If they want to drive it down for no good reason, I'm tempted to avg up. ABCL 3rd stage data! --> 20B MC min. BB Alloy Kore! --> 147 price min. Tickers are unrelated beyond being in Canada and both down today. I'm not leveraged and not leaving.

$ABCL We're doing a pretty good job at treading water while the markets are making some very big adjustments. Would love to see some news\updates from the company to give us a jolt. I want to know what ABCL688 will be for, would love to know managements plan for ABCL 635 phase 3, still waiting for phase 1 readout for ABCL575 too. Happy Tuesday everyone!

$ABCL not sure how you can be bearish this name. Short term price action means nothing. If this drops to $10 or goes up to $20, it will not change the long term. 635 knocked it out of the park. 688 and 386 are coming...

$ABCL good consolidation today, holding up very well considering how red the market is….. one catalyst and we are off to 15+. Be locked and loaded. Any day now!

$ABCL I think the presentation is at 1 AM or so eastern time, incredibly bullish on the stock in the drug, but not expecting anything new out of the presentation and probably minor saw the news. Not going anywhere though Q4 and Q1 of next year we could have nonstop updates on the pipeline and new partnerships. 

$ABCL UBS initiated coverage of AbCellera (ABCL) with a Buy rating and $18 price target The firm believes ABCL635 is a “potentially transformative therapy” in menopausal hot flashes, with a $13B commercial opportunity in menopause by 2035. UBS models $3.3B menopause risk-adjusted 2035 sales versus the consensus at $1.5B. ABCL635 can capture greater share of a larger market than investors currently anticipate, the analyst tells investors in a research note.

$ABCL Still going higher jmho.. Holding every share. Insiders recently loaded it wasnt for $12.5 jmho

$ABCL boys. I usually am very quick on taking profits. But not here. On this one i hold tight. Thing is, this mf can blow up a couple hundred percent in a day or two with the right news.. but same thing applies the other way around. Invest money your ready to lose. Cause this could be the best or worst trade of your life. I never touch biotech, but ABCL got a convincing case going.

$ABCL folks, remain calm. The longs have seen this movie too often. I think a breather was long overdue. If you go back six months ago, we were in the $3 range. Today we are in the $13 range. $10 in six months is something to celebrate and be thankful. Perhaps we need our Moon Guy to cheerlead a little more😜